肝細胞癌(HCC)治療薬の世界市場2022

◆英語タイトル:Global Hepatocellular Carcinoma Drug Sales (Nexavar & Miripla), Pipeline Analysis and Global Market Forecast 2022
◆発行会社/調査会社:RNCOS
◆商品コード:RNCS704005
◆発行日:2017年4月12日
◆調査対象地域:グローバル
◆産業分野:製薬
◆ページ数:70
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Multi UserUSD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はRNCOS社の日本における正規販売代理店です。同社発行の市場調査資料のご購入、委託調査サービスに関するお問い合わせは弊社までお願い致します。
RNCOS社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[肝細胞癌(HCC)治療薬の世界市場2022]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Hepatocellular carcinoma (HCC), also called malignant hepatoma, is the most common type of liver cancer. Most cases of HCC result either from infection with viral hepatitis (Hepatitis B or C), metabolic toxins such as alcohol or aflatoxin, conditions such as hemochromatosis and alpha-deficiency 1-antitrypsin, or NASH.
As per RNCOS report “Global Hepatocellular Carcinoma Drug Sales (Nexavar & Miripla), Pipeline Analysis and Global Market Forecast 2022” the global hepatocellular carcinoma drug market is anticipated to witness a remarkable growth in the coming years. The report provides insights about the major drivers and challenges, along with the latest innovations in this industry. In addition, the report also highlights various opportunities for the growth of the Global Hepatocellular Carcinoma Market.

Key factors supporting the growth of the global hepatocellular carcinoma market include increasing incidences of chronic diseases like infection with hepatitis B or C virus, diabetes, obesity, non-alcoholic fatty liver diseases, and others. Moreover, the growing aging population, adoption of sedentary lifestyle, and increasing R&D investments are also adding up to the growth of global hepatocellular carcinoma market. However, drug failures in pipeline and stringent regulatory challenges are expected to hamper the growth of the global hepatocellular carcinoma drug market.

Furthermore, in this report we have structured the information regarding hepatocellular drugs at various stages of clinical development, totaling to over 350 drugs that are under research or in collaboration and those individually being developed by companies. Out of which, 102 drugs are being developed by industries and rest of the drugs are developed by the research collaborations. The report also provides the segmentation of hepatocellular carcinoma drugs under clinical development on the basis of clinical phase.

As per our research, Nexavar is the only approved targeted drug for the advance hepatocellular carcinoma as of now; with the exception of Miripla approved only in Japan. However, there are molecules in the Phase III clinical development as first-line and second-line treatments, promising to influence the competitive landscape over the next two to three years.

Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America is accounted for the largest share. In addition, Asia-Pacific is projected to be the fastest growing region due to the increasing incidence of chronic disorders, such as cancer, diabetes, hepatitis infections, and others.

Moreover, the report also highlights various mergers and acquisitions taking place in the global hepatocellular carcinoma drug market. The last section of the report discusses about the prominent players in global hepatocellular carcinoma drug market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios. The recent developments of every player have also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global hepatocellular carcinoma drug market.

*** レポート目次(コンテンツ)***

1. Analyst View
2. Research Methodology
3. Hepatocellular Carcinoma- An Introduction
3.1 Etiology and Epidemiology of Hepatocellular Carcinoma
3.2 Risk Factors
4. Market Dynamics
4.1 Drivers
4.1.1 Rising Incidences of Chronic Liver Diseases
4.1.2 Increasing Aging Population
4.1.3 Increasing R&D Investments
4.2 Challenges
4.2.1 Unsuccessful Clinical Trials
4.2.2 Stringent Regulatory Challenges
4.3 Opportunities
4.3.1 Advancement of Cancer Drug Research
4.3.2 Personalized Drug
5. Global Hepatocellular Carcinoma Drug Market Outlook 2022
6. Global Hepatocellular Carcinoma Drug Pipeline Analysis
6.1 Hepatocellular Carcinoma Drug Pipeline by Industries
6.1.1 By Clinical Phase
6.2 Hepatocellular Carcinoma Drug Pipeline by Research and Collaborations
6.2.1 By Clinical Phase
7. Market Segment by Geography
7.1 North America
7.2 Europe
7.3 Asia Pacific
8. Company Profiles
8.1 Pfizer Inc.
8.2 Eli Lilly and Company
8.3 Alnylam Pharmaceuticals, Inc.
8.4 Exelixis, Inc.
8.5 ArQule, Inc.
8.6 Polaris Pharmaceuticals, Inc. (PPI)
8.7 Bayer AG
8.8 Teva Pharmaceutical Industries Ltd.
8.9 Bristol-Mayers Squibb
8.10 Celsion, Inc.

List of Figures:

Figure 4-1: Global – Population 60 Years or Above (Billion), 2015, 2030 & 2050
Figure 5-1: Global – Hepatocellular Carcinoma Drug Market, (Billion US$), 2016 & 2022
Figure 6-1: Global – Hepatocellular Carcinoma Companies Drug Pipeline, by Clinical Phase, (%) 2016
Figure 6-2: Global – Hepatocellular Carcinoma Research Organization Drug Pipeline by Clinical Phase, (%), 2016
Figure 7-1: Global – Hepatocellular Carcinoma Drug Market by Geography (%), 2016
Figure 7-2: North America – Global Hepatocellular Carcinoma Market (Billion US$), 2016 & 2022
Figure 7-3: Europe – Global Hepatocellular Carcinoma Market (Billion US$), 2016 & 2022
Figure 7-4: Asia Pacific – Hepatocellular Carcinoma Drug Market (Billion US$), 2016 & 2022
Figure 8-1: Pfizer Inc. – Revenue by Business Segments (%), 2016
Figure 8-2: Pfizer Inc. – Revenue by Geography (%), 2016
Figure 8-3: Eli Lilly and Company – Revenue by Business Segments (%), 2016
Figure 8-4: Eli Lilly and Company – Revenue by Geography (%), 2016
Figure 8-5: Bayer AG – Revenue by Business Segments (%), 2016
Figure 8-6: Bayer AG – Revenue by Geography (%), 2016
Figure 8-7: Teva Pharmaceutical Industries Ltd. – Revenue by Business Segments (%), 2016
Figure 8-8: Teva Pharmaceutical industries Ltd. – Revenue by Geography (%), 2016
Figure 8-9: Bristol-Mayers Squibb – Revenue by Geography (%), 2016

List of Tables:

Table 5-1: Global – Drugs with Orphan Drugs Status for Hepatocellular Carcinoma
Table 6-1: Global – Hepatocellular Carcinoma Drug in Pipeline by Companies
Table 6-2: Global – Hepatocellular Carcinoma Drug in Pipeline by Research Organization
Table 8-1: Pfizer Inc. – Financials (Million US$), 2014-2016
Table 8-2: Eli Lilly and Company – Financials (Billion US$), 2014-2016
Table 8-3: Alnylam Pharmaceuticals, Inc. – Financials (Billion US$), 2014-2016
Table 8-4: Exelixis, Inc. – Financials (Billion US$), 2014-2016
Table 8-5: Arqule – Financials (Billion US$), 2014-2016
Table 8-6: Bayer AG – Financials (Million US$), 2014-2016
Table 8-7: Teva Pharmaceutical Industries ltd. – Financials (Million US$), 2014-2016
Table 8-8: Bristol-Mayers Squibb – Financials (Billion US$), 2014-2016



*** レポートのキーワード ***

肝細胞癌治療薬

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※H&Iグローバルリサーチは調査サービスを通じて、お客様の海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをご提供しております。
※当市場調査資料"肝細胞癌(HCC)治療薬の世界市場2022"は"RNCOS社"が調査・発行しており、H&Iグローバルリサーチが販売します。お気軽にお問い合わせください。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。